Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 1.00 |
| ▸ | METAP2 | P50579 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CD38 | P28907 | 5/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923839 | 1.00 | PARP1 (1.00) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL29831069 | 0.85 | PARP1 (0.74) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL28154259 | 0.85 | PARP1 (0.74) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL27772010 | 0.84 | PARP1 (0.72) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL5319765 | 0.84 | PARP1 (0.72) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL29412561 | 0.84 | PARP1 (0.72) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL29400398 | 0.82 | PARP1 (0.70) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL5149194 | 0.82 | PARP1 (0.70) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL21816896 | 0.82 | PARP1 (0.70) | PARP1METAP2GAAMAPTCD38 | |
| SCHEMBL27945296 | 0.82 | PARP1 (0.70) | PARP1METAP2GAAMAPTCD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | claimed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | claimed |
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | claimed |
| CN-102316869-A | The treatment method for cancer | AMC AMSTERDAM | 2012-01-11 | — | — | CN | claimed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | claimed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| US-20240105279-A1 | METHODS AND SYSTEMS EMPLOYING TARGETED NEXT GENERATION SEQUENCING FOR CLASSIFYING A TUMOR SAMPLE AS HAVING A LEVEL OF HOMOLOGOUS RECOMBINATION DEFICIENCY SIMILAR TO THAT ASSOCIATED WITH MUTATIONS IN BRCA1 OR BRCA2 GENES | Genomic Testing Cooperative, LCA (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2023039170-A1 | SELECTIVE TARGETING OF CD38 ACTIVITY AS AN IMMUNOSTIMULATORY AND ANTITUMOR STRATEGY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-03-16 | — | — | WO | disclosed |
| US-11278530-B2 | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| EP-3700895-A1 | POLYCYCLIC AMIDES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2020-09-02 | — | — | EP | disclosed |
| CN-105164119-B | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | 苏文生命科学有限公司 | 2017-12-08 | — | — | CN | disclosed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | disclosed |
| CN-102199173-B | 2-benzimidazolyl-8-methanamide quinoline chromium complexes, preparation method and application thereof | CHINESE ACAD INST CHEMISTRY | 2012-09-26 | — | — | CN | disclosed |
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | disclosed |
| CN-102316869-A | The treatment method for cancer | AMC AMSTERDAM | 2012-01-11 | — | — | CN | disclosed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | disclosed |
| CN-102199173-A | 2-benzimidazolyl-8-methanamide quinoline chromium complexes, its preparation method and application | CHINESE ACAD INST CHEMISTRY | 2011-09-28 | — | — | CN | disclosed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278530-B2 | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM5 | PARP1 2034/4885METAP2 2543/4885GAA 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.